Research is the key to ensuring children with cancer have the opportunity to thrive long beyond diagnosis. CURE’s research priorities are two-fold. First, we prioritize research that will lead to more effective treatments for children within two to three years. We also prioritize research aimed at solving recurrent and hard-to-treat cancers for which no effective treatment exists. Precision medicine, gene-based therapy, continues to be our highest priority, as we believe this approach to treatment shows extraordinary promise.
In response to CURE’s request for proposals, we received dozens of studies seeking funding. Our Peer Review Committee, comprised of expert oncologists and academic researchers, reviewed and scored each proposal using the same process employed by the National Institutes of Health. Their scores and critiques guided CURE’s board, ensuring we invest funds in the most strategic and prudent fashion.
We are proud to share that our 2022 research grants are focused almost entirely on helping children facing the toughest diagnoses – high-grade brain tumors, aggressive leukemias and solid tumors, and metastatic disease. These 18 grants awarded to top scientists at leading pediatric cancer research institutions across the nation total more than $4.7 million, CURE’s highest disbursement in a single grant cycle in our 47 year history.
